Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.

Digestive diseases (Basel, Switzerland) - 1 Jan 2000

Nishida Naoshi, Kono Masashi, Minami Tomohiro, Chishina Hirokazu, Arizumi Tadaaki, Takita Masahiro, Yada Norihisa, Ida Hiroshi, Hagiwara Satoru, Minami Yasunori, Ueshima Kazuomi, Sakurai Tashiharu, Kudo Masatoshi

Abstract excerpt

BACKGROUND: An interferon-free regimen including sofosbuvir and ribavirin (RBV) for patients with hepatitis C virus (HCV) genotype 2 (G2) infection leads to a drastic improvement of sustained virological response (SVR). However, the safety, tolerability, and efficacy in patients aged 75 or older have not been completely understood. SUMMARY: Fifty-six patients with HCV G2 infection who were treated with sofosbuvir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glomerular Filtration Rate
Share to Hemoglobins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Ribavirin

Share to Safety

Share to Serum Albumin

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Identifiers

PMID: 27750230
DOI: 10.1159/000448824

Genes

ALB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.PMID 27750230Read ↗

Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.Semantic proximity Read ↗

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.Semantic proximity Read ↗

Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years.Semantic proximity Read ↗

Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.Semantic proximity Read ↗

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.Semantic proximity Read ↗

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.Semantic proximity Read ↗

Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis.Semantic proximity Read ↗

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.Semantic proximity Read ↗

Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.Semantic proximity Read ↗

Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2.Semantic proximity Read ↗

Virologic responses and tolerance of peginterferon alfa plus ribavirin treatment for patients with chronic hepatitis C virus infection in different age categories.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.